Please check your internet connection and try again.
# Genixim (Cefixime)
## Overview
Genixim is a third-generation oral cephalosporin antibiotic. It possesses broad-spectrum activity against Gram-negative organisms and stable activity against many beta-lactamase-producing bacteria.
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Acute bronchitis and acute exacerbations of chronic bronchitis
* Uncomplicated gonorrhea (cervical/urethral/rectal)
## Adult Dosing
* **General infections:** 400 mg daily, administered as a single dose or in two divided doses of 200 mg every 12 hours.
* **Uncomplicated gonorrhea:** 400 mg as a single oral dose.
## Pediatric Dosing
* **General infections (Children > 6 months):** 8 mg/kg/day, administered as a single dose or in two divided doses of 4 mg/kg every 12 hours.
* **Otitis media:** 8 mg/kg/day once daily or in divided doses. Do not exceed 400 mg/day.
## Dose Adjustments
* **Renal Impairment:**
* CrCl 21–60 mL/min: Reduce dose by 25% (or 300 mg daily).
* CrCl < 20 mL/min: Reduce dose by 50% (or 200 mg daily).
* **Hepatic Impairment:** No specific dosage adjustments established.
## Contraindications
* Known hypersensitivity to cefixime or other cephalosporin antibiotics.
* History of severe allergic reactions (anaphylaxis/angioedema) to penicillins or other beta-lactams.
## Adverse Effects
* **Gastrointestinal:** Diarrhea (common), nausea, abdominal pain, dyspepsia.
* **Dermatological:** Rash, pruritus, urticaria.
* **Other:** Headache, dizziness, rarely *Clostridioides difficile*-associated diarrhea.
## Key Drug Interactions
* **Anticoagulants:** May increase the anticoagulant effect of warfarin (monitor INR).
* **Salicylates/Probenecid:** May increase serum concentrations of cefixime by reducing renal tubular secretion.
* **Contraceptives:** Potential risk for reduced efficacy of estrogen-containing oral contraceptives; advise backup barrier method.
## Monitoring
* Monitor for signs of hypersensitivity (skin rashes or severe respiratory distress).
* Assess for persistent diarrhea to rule out *C. difficile* infection.
* Monitor renal function in patients requiring long-term therapy.
## Clinical Pearls
* **Food:** Can be taken with or without food. Taking with food may reduce potential gastrointestinal side effects.
* **Suspension:** Once reconstituted, the oral suspension must be stored at room temperature and discarded after 14 days. Do not refrigerate.
* **Spectrum:** While effective against many *Enterobacteriaceae*, it has poor activity against *Staphylococcus aureus* and *Pseudomonas aeruginosa*.
* **Protocol:** Local antibiotic susceptibility patterns (antibiograms) should guide empirical prescribing decisions, particularly for GNRs in UTIs.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and local resistance patterns change frequently. Always consult the most current official prescribing information (package insert) or local infectious disease protocols before prescribing or administering medication.
